304874-66-6

Basic information

• Product Name: 5-(3-chloro-phenyl)-1,3-dihydro-indol-2-one
• Synonyms: 5-(3-chloro-phenyl)-1,3-dihydro-indol-2-one
• CAS NO: 304874-66-6
• Molecular Weight: 243.692
• Mol File: 304874-66-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 5-(3-chloro-phenyl)-1,3-dihydro-indol-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(3-chloro-phenyl)-1,3-dihydro-indol-2-one(304874-66-6)
• EPA Substance Registry System: 5-(3-chloro-phenyl)-1,3-dihydro-indol-2-one(304874-66-6)

Safety Data

• Hazardous Substances Data: 304874-66-6(Hazardous Substances Data)

Upstream product

• 14221-01-3 tetrakis(triphenylphosphine) palladium⁽⁰⁾ 
• 20870-78-4 5-bromo-2-indolin-2-one 
• 63503-60-6 3-chlorophenylboronic acid 
• 59-48-3 2-oxoindole 

Downstream Products

• 304876-14-0 5-[3-chloro-phenyl]-1H-indole-2,3-dione 

Relevant articles and documents

New progesterone receptor antagonists: 3,3-disubstituted-5-aryloxindoles.

A new series of 3,3-disubstituted-5-aryloxindoles has been synthesized and evaluated for progesterone receptor antagonist (PR) activity in a T47D cell alkaline phosphatase assay and for their ability to bind PR in competition binding studies. In this comm

CYCLIC REGIMENS UTILIZING INDOLINE DERIVATIVES

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R 1 and R 2 may be single substituents or fused to form spirocyclic rings, in combination with progestins, estrogens, or both. These methods of treatment may be used for contraception or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minimization of side effects or cyclic menstrual bleeding. Additional uses of the invention include stimulation of food intake.